$PPBT so I remain puzzled about the 6 mg dose data. We know it has been done for awhile but not yet released. We know it’s not bad bc the trials are moving forward. What if it’s too good. That is, PPBT knows if it releases that data, it will get a BO offer it can’t refuse, but it’s going to be lower than what PPBT thinks its worth. Just a theory and perhaps too much hopium this evening, but I would welcome anyone else’s theory about why the 6 mg data has not been released yet…
@lostinatown I think they're seeing better and better results as the dosage escalates, and are therefore delaying readouts to get the higher mg in there (Hence why Isaac was so giddy about monotherapy). Remember that in preclinical, 60mg monotherapy NT219 completely flattened the curve.